|
1) Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002; 62: 4645-55
|
|
|
|
2) Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thoracic Oncol. 2006; 1: 1002-9
|
|
|
|
|
|
3) Nakagawa K, Kiura T, Shinkai K, et al. A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. Proc Am Soc Clin Oncol. 2006: abst 7067
|
|
|
|
|
|
4) Heymach JV, Johnson BE, Prager D, et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Proc Am Soc Clin Oncol. 2006: abst 7016
|
|
|
|
|
|
5) Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 2004; 64: 9101-4
|
|
|
|
|
6) Wilhelm S, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum anti-tumor activity and targets raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64: 7099-109
|
|
|
|
|
|
7) Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol. 2006; 23: 965-72
|
|
|
|
|
|
8) Escudier B, Eisen T, Stadler WM, et al. Sorafanib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-34
|
|
|
|
|
|
9) Gatzemeier U, Blumenschein G, Fossella F, et al. Phase II study of single agent sorafenib in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol. 2006
|
|
|
|
|
|
10) Schiller J, Flaherty KT, Redlinger M, et al. Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer: a phase I subset analysis. Proc Am Soc Clin Oncol. 2006
|
|
|
|
|
|
11) Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003; 9: 327-37
|
|
|
|
|
|
12) Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-24
|
|
|
|
|
|
13) Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006; 368: 1329-38
|
|
|
|
|
|
14) Socinski MA, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. Proc Am Soc Clin Oncol. 2006: abst 7001
|
|
|
|
|